Subscribe to our Newsletters !!
In the era of changing pharmaceutical innovation p
The pharmaceutical sector is on the cusp of a new
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
A few months b Pharma News
A few months b
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Pune, Sep 19 (PTI) The phase-III human clinical trial of the COVID-19 vaccine developed by Oxford University and being fabricated by the Serum Institute of India (SII) will begin at the Sassoon General Hospital in Pune next week.
“The phase-III trial of”Covishield” vaccine will start in Sassoon hospital from next week. It’s likely to start on Monday. Some volunteers have already come forward for the trial. Around 150 to 200 volunteers will be administered the vaccine candidate dose,” he said.
“From Saturday, the hospital started enrolling volunteers for the trial. Those people who would like to volunteer for the vaccination should contact the hospital,” he said.
Under phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city.
The SII has partnered with British-Swedish pharma firm AstraZeneca for fabricating the COVID-19 vaccine candidate, developed by the University of Oxford.
Earlier this month, the SII had ceased the clinical trials of this vaccine candidate in the nation.
The Drugs Controller General of India (DCGI) had on September 11 directed the SII to suspend any new recruitment in the phase-II and III clinical trial of the vaccine till further orders after AstraZeneca stopped the trials in different countries due to”an unexplained illness” in a participant in the research.
However, on September 15, the DCGI gave permission to the SII to restart clinical trial of the vaccine.
